Acute fulminant hepatitis after treatment with rabeprazole and terbinafine.
Johnstone
D
D
Berger
C
C
Fleckman
P
P
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D000935:Antifungal Agents / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D056487:Chemical and Drug Induced Liver Injury, Chronic / Q000175:diagnosis / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects*; D009853:Omeprazole / Q000031:analogs & derivatives; D064750:Rabeprazole; D000077291:Terbinafine
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D000935:Antifungal Agents; D001562:Benzimidazoles; D009281:Naphthalenes; D064750:Rabeprazole; D000077291:Terbinafine; D009853:Omeprazole